Радиочастотная катетерная аблация и антиаритмическая терапия в лечении пациентов с пароксизмальной и персистирующей формой фибрилляции предсердий: клинические эффекты

1. Hrafnhildur S, Thor A, Vilmundur G, David OA. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace 2011; 13: 1110–7.
2. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516–21.
3. Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042–6.
4. Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119–25.
5. Nabauer M, Gerth A, Limbourg T et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11: 423–34.
6. Pillarisetti J, Lakkireddy D. Atrial fibrillation in Europe: state of the state in disease management! Eur Heart J 2014; 35: 3326–7.
7. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation – a translational appraisal. Physiological Reviews 2011; 91 (1): 265–325.
8. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. JACC 2014. Doi: 10.1016/j.jacc.2014.03.022.
9. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834–40.
10. The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347 (23): 1825–33.
11. Corley SD, Epstein AE, DiMarco JP et al. (AFFIRM Investigators) Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109 (12): 1509–13.
12. Hagens VE, Van Gelder IC, Crijns HJ. RAte Control Versus Electrical Cardioversion Of Persistent Atrial Fibrillation (RACE) Study Group. Card Electrophysiol Review 2003; 7 (2): 118–21.
13. Carlsson J, Miketic S, Windeler J et al. Randomized trial of rate control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. JACC 2003; 41 (10): 1690–6.
14. Сулимов В.А., Голицин С.П., Панченко Е.П. и др. Диагностика и лечение фибрилляции предсердий. Клинические рекомендации. Рос. кардиол. журн. 2013; 4 (102; Прил. 3). / Sulimov V.A., Golitsin S.P., Panchenko E.P. i dr. Diagnostika i lechenie fibrilliatsii predserdii. Klinicheskie rekomendatsii. Ros. kardiol. zhurn. 2013; 4 (102; Pril. 3). [in Russian]
15. Calkins H, Kuck KH, Cappato R et al. 2012 HRS/EHRA/ECAS Expert Consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012; 14 (4): 528–606.
16. Noheria A, Kumar A, Wylie JV, Jr. Josephson ME. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med 2008; 168: 581–6.
17. Wazni OM, Marrouche NF, Martin DO et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293 (21): 2634–40.
18. Pappone C, Augello G, Sala S, Gugliotta F et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: The APAF Study. JACC 2006; 48 (11): 2340–7.
19. Calkins H, Reynolds MR, Spector P et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009; 2 (4): 349–61.
20. Brooks AG, Stiles MK, Laborderie J et al. Outcomes of long-standing persistent atrial fibrillation ablation: A systematic review. Heart Rhythm 2010; 7 (6): 835–46.
21. Bonanno C, Paccanaro M, La Vecchia L et al. Efficacy and safety of catheter ablation versus antiarrhythmic drugs for atrial fibrillation: a meta-analysis of randomized trials. J Cardiovasc Med (Hagerstown). 2010; 11 (6): 408–18.
22. Shah AN, Mittal S, Sichrovsky TC et al. Long-term outcome following successful pulmonary vein isolation: pattern and prediction of very late recurrence. J Cardiovasc Electrophysiol 2008; 19 (7): 661–7.
23. Ouyang F, Tilz R, Chun J et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation 2010; 122: 2368–77.
24. Nielsen JC, Johannessen А, Raatikainen P et al. Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation. N Engl J Med 2012; 367: 1587–95.
25. Hummel J, Michaud G, Hoyt R et al. Phased RF ablation in persistent atrial fibrillation. Heart Rhythm 2014; 11: 202–9.
26. Wokhlu A, Hodge DO, Monahan KH et al. Long-term outcome of atrial fibrillation ablation: impact and predictors of very late recurrence. J Cardiovasc Electrophysiol 2010; 21 (10): 1071–8.
27. Haegeli LM, Calkins H. Catheter ablation of atrial fibrillation: an update. Eur Heart J 2014; 35: 2454–9.
28. Themistoclakis S, Schweikert RA, Saliba WI et al. Clinical predictors and relationship between early and late atrial tachyarrhythmias after pulmonary vein antrum isolation. Heart Rhythm 2008; 5 (5): 679–85.
29. Oral H, Knight BP, Ozaydin M et al. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol 2002; 40 (1):100–4.
30. Grubman E, Pavri BB, Lyle S et al. Histopathologic effects of radiofrequency catheter ablation in previously infarcted human myocardium. J Cardiovasc Electrophysiol 1999; 10 (3): 336–42.
31. Hsieh MH, Chiou CW, Wen ZC et al. Alterations of heart rate variability after radiofrequency catheter ablation of focal atrial fibrillation originating from pulmonary veins. Circulation 1999; 100 (22): 2237–43.
32. Andrade JG, Khairy P, Verma A et al. Early recurrence of atrial tachyarrhythmias following radiofrequency catheter ablation of atrial fibrillation. Pacing Clin Electrophysiol 2012; 35 (1): 106–16.
33. Verma A, Kilicaslan F, Pisano E et al. Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction. Circulation 2005; 112 (5): 627–35.
34. Salghetti F, Vizzardi E, Elmaghawry M et al. Need for Ongoing Anti Arrhythmic Drugs After Ablation of Atrial Fibrillation. Review. Recent Patents on Cardiovascular Drug Discovery 2013; 8: 204–15.
35. Heidbuchel H, Hindricks G. The year in cardiology 2014: arrhythmias and device therapy. Eur Heart J 2015; 36: 270–8.
36. Cai L, Yin Y, Ling Z, Su L et al. Predictors of late recurrence of atrial fibrillation after catheter ablation. Int J Cardiol 2013; 164 (1): 82–7.
37. Leong-Sit P, Roux JF, Zado E et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study. Circ Arrhythm Electrophysiol 2011; 4 (1): 11–4.
38. Berkowitsch A, Greiss H, Vukajlovic D, Kuniss M et al. Usefulness of atrial fibrillation burden as a predictor for success of pulmonary vein isolation. Pacing Clin Electrophysiol 2005; 28 (12): 1292–301.
39. Pokushalov E, Romanov A, De Melis M et al. Progression of atrial fibrillation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation: a randomized comparison of drug therapy versus reablation. Circ Arrhythm Electrophysiol 2013; 6 (4): 754–60.
40. Kerr CR, Humphries KH, Talajic M et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005; 149: 489–96.
41. De Vos CB, Pisters R, Nieuwlaat R et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010; 55: 725–31.
42. Weerasooriya R, Khairy P, Litalien J et al. Catheter ablation for atrial fibrillation: Are results maintained at 5 years of follow-up? JAСC 2011; 57 (2): 160–6.
43. Ganesan А, Shipp NJ, Brooks AG et al. Long-term Outcomes of Catheter Ablation of Atrial Fibrillation: A Systematic Review and Meta-analysis. J Am Heart Assoc 2013; 2: e004549 Doi: 10.1161/JAHA.112.004549.
44. Gu J, Liu X, Tan H et al. Extensive antiarrhythmic drugs after catheter ablation of persistent atrial fibrillation. Acta Cardiol 2012; 67 (4): 407–14.
45. Baman TS, Gupta SK, Billakanty SR et al. Time to cardioversion of recurrent atrial arrhythmias after catheter ablation of atrial fibrillation and long-term clinical outcome. J Cardiovasc Electrophysiol 2009; 20 (12): 1321–5.
46. Choi JI, Pak HN, Park JS et al. Clinical significance of early recurrences of atrial tachycardia after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2010; 21 (12): 1331–7.
47. Roux JF, Zado E, Callans DJ et al. Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study). Circulation 2009; 120 (12): 1036–40.
48. Kumagai K, Ogawa M, Noguchi H et al. Electrophysiologic properties of pulmonary veins assessed using a multielectrode basket catheter. J Am Coll Cardiol 2004; 43 (12): 2281–9.
49. Cappato R, Calkins H, Chen SA et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3 (1): 32–8.
50. Hayashi M, Miyauchi Y, Iwasaki YK et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace 2014; 16 (8): 1160–7.
51. Darkner S, Chen X, Hansen J, Pehrson S et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). Eur Heart J 2014; 35 (47): 3356–64.
52. Тарасов А.В., Давтян К.В., Махинова М.М. Результаты применения пропафенона в раннем послеоперационном периоде катетерной радиочастотной изоляции устьев легочных вен для предупреждения ранних предсердных тахиаритмий. КардиоСоматика. 2015; 6 (2): 47–52. / Tarasov A.V., Davtian K.V., Makhinova M.M. Results of propafenone use in early postoperative period after pulmonary veins catheter radiofrequency isolation for prevention of early atrial tachyarrhythmias. Cardiosomatics. 2015; 6 (2): 47–52.
53. Rordorf R, Savastano S, Gandolfi E et al. Pharmacological therapy following catheter ablation of atrial fibrillation. J Cardiovasc Med (Hagerstown) 2012; 13 (1): 9–15.
54. Stabile G, Iuliano A, Agresta A et al. Antiarrhythmic therapy following ablation of atrial fibrillation.Expert Rev Cardiovasc Ther 2013; 11 (7): 837–42.
55. Arbelo E, Brugada J, Hindricks G et al. Atrial Fibrillation Ablation Pilot Study I. The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J 2014; 35: 1466–78.

________________________________________________

1. Hrafnhildur S, Thor A, Vilmundur G, David OA. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace 2011; 13: 1110–7.
2. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516–21.
3. Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042–6.
4. Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119–25.
5. Nabauer M, Gerth A, Limbourg T et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11: 423–34.
6. Pillarisetti J, Lakkireddy D. Atrial fibrillation in Europe: state of the state in disease management! Eur Heart J 2014; 35: 3326–7.
7. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation – a translational appraisal. Physiological Reviews 2011; 91 (1): 265–325.
8. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. JACC 2014. Doi: 10.1016/j.jacc.2014.03.022.
9. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834–40.
10. The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347 (23): 1825–33.
11. Corley SD, Epstein AE, DiMarco JP et al. (AFFIRM Investigators) Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109 (12): 1509–13.
12. Hagens VE, Van Gelder IC, Crijns HJ. RAte Control Versus Electrical Cardioversion Of Persistent Atrial Fibrillation (RACE) Study Group. Card Electrophysiol Review 2003; 7 (2): 118–21.
13. Carlsson J, Miketic S, Windeler J et al. Randomized trial of rate control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. JACC 2003; 41 (10): 1690–6.
14. Sulimov V.A., Golitsin S.P., Panchenko E.P. i dr. Diagnostika i lechenie fibrilliatsii predserdii. Klinicheskie rekomendatsii. Ros. kardiol. zhurn. 2013; 4 (102; Pril. 3). [in Russian]
15. Calkins H, Kuck KH, Cappato R et al. 2012 HRS/EHRA/ECAS Expert Consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012; 14 (4): 528–606.
16. Noheria A, Kumar A, Wylie JV, Jr. Josephson ME. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med 2008; 168: 581–6.
17. Wazni OM, Marrouche NF, Martin DO et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293 (21): 2634–40.
18. Pappone C, Augello G, Sala S, Gugliotta F et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: The APAF Study. JACC 2006; 48 (11): 2340–7.
19. Calkins H, Reynolds MR, Spector P et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009; 2 (4): 349–61.
20. Brooks AG, Stiles MK, Laborderie J et al. Outcomes of long-standing persistent atrial fibrillation ablation: A systematic review. Heart Rhythm 2010; 7 (6): 835–46.
21. Bonanno C, Paccanaro M, La Vecchia L et al. Efficacy and safety of catheter ablation versus antiarrhythmic drugs for atrial fibrillation: a meta-analysis of randomized trials. J Cardiovasc Med (Hagerstown). 2010; 11 (6): 408–18.
22. Shah AN, Mittal S, Sichrovsky TC et al. Long-term outcome following successful pulmonary vein isolation: pattern and prediction of very late recurrence. J Cardiovasc Electrophysiol 2008; 19 (7): 661–7.
23. Ouyang F, Tilz R, Chun J et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation 2010; 122: 2368–77.
24. Nielsen JC, Johannessen А, Raatikainen P et al. Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation. N Engl J Med 2012; 367: 1587–95.
25. Hummel J, Michaud G, Hoyt R et al. Phased RF ablation in persistent atrial fibrillation. Heart Rhythm 2014; 11: 202–9.
26. Wokhlu A, Hodge DO, Monahan KH et al. Long-term outcome of atrial fibrillation ablation: impact and predictors of very late recurrence. J Cardiovasc Electrophysiol 2010; 21 (10): 1071–8.
27. Haegeli LM, Calkins H. Catheter ablation of atrial fibrillation: an update. Eur Heart J 2014; 35: 2454–9.
28. Themistoclakis S, Schweikert RA, Saliba WI et al. Clinical predictors and relationship between early and late atrial tachyarrhythmias after pulmonary vein antrum isolation. Heart Rhythm 2008; 5 (5): 679–85.
29. Oral H, Knight BP, Ozaydin M et al. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol 2002; 40 (1):100–4.
30. Grubman E, Pavri BB, Lyle S et al. Histopathologic effects of radiofrequency catheter ablation in previously infarcted human myocardium. J Cardiovasc Electrophysiol 1999; 10 (3): 336–42.
31. Hsieh MH, Chiou CW, Wen ZC et al. Alterations of heart rate variability after radiofrequency catheter ablation of focal atrial fibrillation originating from pulmonary veins. Circulation 1999; 100 (22): 2237–43.
32. Andrade JG, Khairy P, Verma A et al. Early recurrence of atrial tachyarrhythmias following radiofrequency catheter ablation of atrial fibrillation. Pacing Clin Electrophysiol 2012; 35 (1): 106–16.
33. Verma A, Kilicaslan F, Pisano E et al. Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction. Circulation 2005; 112 (5): 627–35.
34. Salghetti F, Vizzardi E, Elmaghawry M et al. Need for Ongoing Anti Arrhythmic Drugs After Ablation of Atrial Fibrillation. Review. Recent Patents on Cardiovascular Drug Discovery 2013; 8: 204–15.
35. Heidbuchel H, Hindricks G. The year in cardiology 2014: arrhythmias and device therapy. Eur Heart J 2015; 36: 270–8.
36. Cai L, Yin Y, Ling Z, Su L et al. Predictors of late recurrence of atrial fibrillation after catheter ablation. Int J Cardiol 2013; 164 (1): 82–7.
37. Leong-Sit P, Roux JF, Zado E et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study. Circ Arrhythm Electrophysiol 2011; 4 (1): 11–4.
38. Berkowitsch A, Greiss H, Vukajlovic D, Kuniss M et al. Usefulness of atrial fibrillation burden as a predictor for success of pulmonary vein isolation. Pacing Clin Electrophysiol 2005; 28 (12): 1292–301.
39. Pokushalov E, Romanov A, De Melis M et al. Progression of atrial fibrillation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation: a randomized comparison of drug therapy versus reablation. Circ Arrhythm Electrophysiol 2013; 6 (4): 754–60.
40. Kerr CR, Humphries KH, Talajic M et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005; 149: 489–96.
41. De Vos CB, Pisters R, Nieuwlaat R et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010; 55: 725–31.
42. Weerasooriya R, Khairy P, Litalien J et al. Catheter ablation for atrial fibrillation: Are results maintained at 5 years of follow-up? JAСC 2011; 57 (2): 160–6.
43. Ganesan А, Shipp NJ, Brooks AG et al. Long-term Outcomes of Catheter Ablation of Atrial Fibrillation: A Systematic Review and Meta-analysis. J Am Heart Assoc 2013; 2: e004549 Doi: 10.1161/JAHA.112.004549.
44. Gu J, Liu X, Tan H et al. Extensive antiarrhythmic drugs after catheter ablation of persistent atrial fibrillation. Acta Cardiol 2012; 67 (4): 407–14.
45. Baman TS, Gupta SK, Billakanty SR et al. Time to cardioversion of recurrent atrial arrhythmias after catheter ablation of atrial fibrillation and long-term clinical outcome. J Cardiovasc Electrophysiol 2009; 20 (12): 1321–5.
46. Choi JI, Pak HN, Park JS et al. Clinical significance of early recurrences of atrial tachycardia after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2010; 21 (12): 1331–7.
47. Roux JF, Zado E, Callans DJ et al. Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study). Circulation 2009; 120 (12): 1036–40.
48. Kumagai K, Ogawa M, Noguchi H et al. Electrophysiologic properties of pulmonary veins assessed using a multielectrode basket catheter. J Am Coll Cardiol 2004; 43 (12): 2281–9.
49. Cappato R, Calkins H, Chen SA et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3 (1): 32–8.
50. Hayashi M, Miyauchi Y, Iwasaki YK et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace 2014; 16 (8): 1160–7.
51. Darkner S, Chen X, Hansen J, Pehrson S et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). Eur Heart J 2014; 35 (47): 3356–64.
52. Tarasov A.V., Davtian K.V., Makhinova M.M. Results of propafenone use in early postoperative period after pulmonary veins catheter radiofrequency isolation for prevention of early atrial tachyarrhythmias. Cardiosomatics. 2015; 6 (2): 47–52.
53. Rordorf R, Savastano S, Gandolfi E et al. Pharmacological therapy following catheter ablation of atrial fibrillation. J Cardiovasc Med (Hagerstown) 2012; 13 (1): 9–15.
54. Stabile G, Iuliano A, Agresta A et al. Antiarrhythmic therapy following ablation of atrial fibrillation.Expert Rev Cardiovasc Ther 2013; 11 (7): 837–42.
55. Arbelo E, Brugada J, Hindricks G et al. Atrial Fibrillation Ablation Pilot Study I. The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J 2014; 35: 1466–78.

М.Г.Бубнова*, Д.М.Аронов, М.М.Махинова

ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава России. 101990, Россия, Москва, Петроверигский пер., д. 10, стр. 3
*mbubnova@gnicpm.ru

________________________________________________

M.G.Bubnova*, D.M.Aronov, M.M.Makhinova

State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation. 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3
*mbubnova@gnicpm.ru